Related Experiment Video

Updated: May 4, 2026

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.2K

miR-338-3p suppresses gastric cancer progression through a PTEN-AKT axis by targeting P-REX2a

Bo Guo1, Liying Liu, Jiayi Yao

  • 1Xi'an Jiaotong University College of Medicine, Yanta Western Road 76, Xi'an 710061, China. hchen@mail.xjtu.edu.cn.

Molecular Cancer Research : MCR
|December 31, 2013
PubMed
Abstract

Insights

MicroRNA-338-3p (miR-338-3p) is downregulated in gastric cancer and acts as a tumor suppressor. It inhibits cancer cell growth by targeting P-Rex2a and activating PTEN-AKT signaling, offering a new treatment strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Aberrant microRNA (miRNA) expression is observed in various cancers.
  • While miR-338-3p is linked to liver cancer, its function in gastric cancer remains unclear.

Purpose of the Study:

  • To investigate the role and mechanism of miR-338-3p in gastric cancer progression.

Main Methods:

  • Quantitative real-time PCR to assess miR-338-3p levels in gastric cancer tissues and cell lines.
  • Cell proliferation, clonogenicity, cell cycle, and apoptosis assays.
  • Western blotting to analyze protein expression and signaling pathways (PTEN, AKT).
  • In vivo tumor xenograft assays in nude mice.

Main Results:

  • miR-338-3p was significantly downregulated in gastric cancer tissues and cell lines.
  • Forced miR-338-3p expression suppressed gastric cancer cell proliferation, clonogenicity, induced G1-S arrest, and promoted apoptosis.
  • P-Rex2a was identified as a direct target of miR-338-3p; silencing P-Rex2a mimicked miR-338-3p effects.
  • miR-338-3p and P-Rex2a silencing activated PTEN, reducing AKT phosphorylation.
  • miR-338-3p inhibited tumor growth in vivo.

Conclusions:

  • miR-338-3p functions as a tumor suppressor in gastric cancer.
  • It inhibits gastric cancer progression by targeting P-Rex2a and modulating the PTEN-AKT signaling pathway.
  • miR-338-3p represents a potential therapeutic target for gastric cancer treatment.

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.1K
Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

9.1K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K